GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Inventories, Other

Exelixis (FRA:EX9) Inventories, Other : €19 Mil (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Exelixis's other inventories for the quarter that ended in Mar. 2024 was €19 Mil.

Exelixis's quarterly other inventories declined from Sep. 2023 (€23 Mil) to Dec. 2023 (€16 Mil) but then increased from Dec. 2023 (€16 Mil) to Mar. 2024 (€19 Mil).

Exelixis's annual other inventories increased from Dec. 2021 (€24 Mil) to Dec. 2022 (€31 Mil) but then declined from Dec. 2022 (€31 Mil) to Dec. 2023 (€16 Mil).


Exelixis Inventories, Other Historical Data

The historical data trend for Exelixis's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Inventories, Other Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.60 17.24 24.33 31.43 15.89

Exelixis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.93 26.43 23.40 15.89 19.42

Exelixis Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Exelixis (FRA:EX9) Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (FRA:EX9) Headlines

No Headlines